Protalix BioTherapeutics, Inc. (PLX)
NYSEAMERICAN: PLX · Real-Time Price · USD
2.510
-0.180 (-6.69%)
Nov 5, 2026, 4:00 PM EST - Market closed
Protalix BioTherapeutics Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, Protalix BioTherapeutics stock has an average price target of $11. The average 1-year stock price forecast is 338.25% higher than the current stock price, while the lowest is $10 (+298.41%) and the highest is $12 (+378.09%).
Price Target: $11 (+338.25%)
Analyst Consensus: n/a
Price Target
ChartAnalyst Ratings
According to 1 stock analyst, the rating for Protalix BioTherapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | May '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $12 | Buy | Reiterates | $12 | +378.09% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
68.66M
from 52.74M
Increased by 30.17%
Revenue Next Year
65.48M
from 68.66M
Decreased by -4.63%
EPS This Year
n/a
EPS Next Year
n/a